Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

508 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Relationship between patterns of immunohistochemical conventional neuroendocrine markers and efficacy of immune check point inhibitors in patients with extensive disease small cell lung cancer.
Iida Y, Wakuda K, Kawata T, Morita M, Sekikawa M, Doshita K, Yabe M, Kodama H, Miura K, Morikawa N, Mamesaya N, Kobayashi H, Ko R, Ono A, Kenmotsu H, Naito T, Murakami H, Gon Y, Takahashi T. Iida Y, et al. Among authors: ko r. Thorac Cancer. 2024 Feb;15(6):477-485. doi: 10.1111/1759-7714.15218. Epub 2024 Jan 19. Thorac Cancer. 2024. PMID: 38243641 Free PMC article.
The effect of gefitinib in patients with postoperative recurrent non-small cell lung cancer harboring mutations of the epidermal growth factor receptor.
Ko R, Kenmotsu H, Hisamatsu Y, Akamatsu H, Omori S, Nakashima K, Oyakawa T, Wakuda K, Shukuya T, Ono A, Imai H, Taira T, Naito T, Murakami H, Mori K, Endo M, Ohde Y, Takahashi K, Takahashi T. Ko R, et al. Int J Clin Oncol. 2015 Aug;20(4):668-73. doi: 10.1007/s10147-014-0761-8. Epub 2014 Oct 25. Int J Clin Oncol. 2015. PMID: 25343946
Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients.
Ko R, Kenmotsu H, Serizawa M, Koh Y, Wakuda K, Ono A, Taira T, Naito T, Murakami H, Isaka M, Endo M, Nakajima T, Ohde Y, Yamamoto N, Takahashi K, Takahashi T. Ko R, et al. BMC Cancer. 2016 Nov 8;16(1):864. doi: 10.1186/s12885-016-2902-0. BMC Cancer. 2016. PMID: 27821131 Free PMC article.
Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
Hayakawa D, Takahashi F, Mitsuishi Y, Tajima K, Hidayat M, Winardi W, Ihara H, Kanamori K, Matsumoto N, Asao T, Ko R, Shukuya T, Takamochi K, Hayashi T, Suehara Y, Takeda Nakamura I, Ueno T, Kohsaka S, Mano H, Takahashi K. Hayakawa D, et al. Among authors: ko r. Thorac Cancer. 2020 Jan;11(1):140-149. doi: 10.1111/1759-7714.13255. Epub 2019 Nov 22. Thorac Cancer. 2020. PMID: 31758670 Free PMC article.
A randomized phase 3 study of maintenance therapy with S-1 plus best supportive care versus best supportive care after induction therapy with carboplatin plus S-1 for advanced or relapsed squamous cell carcinoma of the lung (WJOG7512L).
Tanaka K, Morita S, Ando M, Yokoyama T, Nakamura A, Yoshioka H, Ishiguro T, Miura S, Toyozawa R, Oguri T, Daga H, Ko R, Bessho A, Tachihara M, Iwamoto Y, Hirano K, Nakanishi Y, Nakagawa K, Yamamoto N, Okamoto I. Tanaka K, et al. Among authors: ko r. Cancer. 2020 Aug 15;126(16):3648-3656. doi: 10.1002/cncr.32987. Epub 2020 Jun 2. Cancer. 2020. PMID: 32484914 Free article. Clinical Trial.
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.
Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS; ADAURA Investigators. Wu YL, et al. N Engl J Med. 2020 Oct 29;383(18):1711-1723. doi: 10.1056/NEJMoa2027071. Epub 2020 Sep 19. N Engl J Med. 2020. PMID: 32955177 Clinical Trial.
508 results